Streetbeat News

LUMO

Lumos Pharma, Inc.

https://www.lumos-pharma.com

Industry

Biotechnology

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Open

4.34

Mkt cap

37M

Volume

102K

High

4.39

P/E Ratio

-1.01

52-wk high

4.58

Low

4.30

Div yield

N/A

52-wk low

1.37

Lumos Pharma's updated analysis from its Phase 2 OraGrowtH210 trial will be presented at the APPES 2024 meeting, focusing on LUM-201 for Pediatric Growth Hormone Deficiency.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:08 pm

EF Hutton has initiated coverage on Lumos Pharma with a Buy rating and set a price target of $16, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:51 pm

Oppenheimer analyst Leland Gershell maintains an Outperform rating on Lumos Pharma (NASDAQ:LUMO) but lowers the price target from $16 to $13.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 3:50 pm

Lumos Pharma (NASDAQ:LUMO) reported Q2 2024 GAAP EPS of $(0.93), beating the estimate of $(1.24). Sales were $488.000K, surpassing the $333.333K estimate. Despite a year-over-year sales decrease, the results show significant improvement over analyst expectations.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 8:40 pm

Lumos Pharma has reported new analyses of its Phase 2 OraGrowtH212 trial at the ENDO 2024 conference. The trial focuses on evaluating the efficacy and safety of LUM-201 in pediatric growth hormone deficiency.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 1:01 pm

Lumos Pharma (LUMO) reported Q1 2024 GAAP EPS of $(1.29), missing the $(1.18) estimate, with sales of $165.00K also missing the $302.60K estimate, marking a 76.12% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:53 pm

Lumos Pharma has announced a successful end-of-Phase 2 meeting with the FDA regarding its ongoing drug development. The company expects to finalize the trial design details with the FDA in Q3 and aims to initiate the next trial phase before the end of the year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:17 pm

Lumos Pharma has announced that abstracts reviewing data from its Phase 2 OraGrowth210 and OraGrowth212 trials will be presented at upcoming medical meetings. This development could indicate progress in their research and potential for future growth.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 8:08 pm

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Lumos Pharma (NASDAQ:LUMO) and maintained a $28 price target.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 4:29 pm

Lumos Pharma has received a patent from the USPTO for a novel formulation of LUM-201, extending its exclusivity until 2042. This development could significantly impact Lumos Pharma's market position by potentially increasing its revenue streams and strengthening its competitive edge in the pharmaceutical industry through extended market exclusivity of LUM-201.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 12:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.